⚡🫀 Shock. Silence. Success — A landmark New England Journal of Medicine trial redefines first-line therapy in persistent AF.

In AVANT GUARD, pulsed field ablation (PFA) outperformed antiarrhythmic drugs: 📊 Success: 56% vs 30% 📉 HR: 0.46 (P 💓 Lower arrhythmia burden (−6.5%)

Safety remained comparable, with primary events at 5.1%.

A compelling case for early, energy-based rhythm control—precision over pharmacology.

#Cardiology #Electrophysiology #AtrialFibrillation #NEJM #Innovation